Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 256 participants.
Also called NCT05624190
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 256 participants
- Sponsor
- Registry
-
NCT05624190
-
- Other papers using this trial's data
- Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy: The ANGEL-TNK Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05624190. Randomized; single masking; primary purpose treatment. Start 2023-02-16 (actual); primary completion 2024-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization
- Acronym
- ANGEL-TNK
- Condition
- Ischemic Stroke, Acute
- Intervention (Drug)
- Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)
- Intervention (Other)
- Best Medical Management
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct05624190- Content hash
2b5b75339334c21ae21cdebebb8c6fc6ea4cb187f5db7945464fce93b9f82731